EJCTS Click here for details of sales representative
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Thomas Schachner
Johannes Bonatti
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schachner, T.
Right arrow Articles by Bonatti, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schachner, T.
Right arrow Articles by Bonatti, J.
Related Collections
Right arrow Coronary disease
Right arrow Molecular biology

Eur J Cardiothorac Surg 2006;30:451-463
© 2006 Elsevier Science NL


Review

In vivo (animal) models of vein graft disease

Thomas Schachner*, Günther Laufer, Johannes Bonatti

Department of Cardiac Surgery, Innsbruck Medical University, Innsbruck, Austria

Received 30 September 2005; received in revised form 2 May 2006; accepted 11 June 2006.

* Corresponding author. Address: Anichstrasse 35, 6020 Innsbruck, Austria. Tel.: +43 5125040; fax: +43 51250422528. (Email: Thomas.Schachner{at}uibk.ac.at).

Despite the very important use of arterial bypass conduits, vein grafts remain one cornerstone in coronary surgery. Newer studies show a saphenous vein graft patency of about 60% at 10 years postoperatively. This article reviews the in vivo (animal) models of vein graft disease. According to the different models, the findings on pathology of graft thrombosis, neointimal hyperplasia, and vein graft atherosclerosis are summarized. Therapeutic strategies to prevent vein graft disease (including external stenting, pharmacotherapy, and gene therapy) are reviewed.

Abbreviations: ACE = angiotensin converting enzyme • apoE = apolipoprotein E • bFGF = basic fibroblast growth factor • BrdU = 5-bromo-2’-deoxyuridine • CABG = coronary artery bypass graft • cAMP = cyclic adenosine monophosphate • cdc2 kinase = cell division cycle 2 kinase • cGMP = cyclic guanosine monophosphate • CNP = C-type natriuretic peptide • ET = endothelin • ERK-1/2 = extracellular signal-regulated kinase • G-protein = guanine nucleotide binding protein • HVJ = hemagglutinating virus of Japan • ICAM-1 = intercellular adhesion molecule-1 • IL = interleukin • IGF-1 = insulin-like growth factor 1 • ITA = internal thoracic artery • JNK = c-jun N-terminal kinases • LTB4 = leukotriene B4 • MAPK = mitogen-activated protein kinases • MMP = matrix metalloproteinase • mRNA = messenger ribonucleic acid • NOS = nitric oxide synthase • ODN = oligodeoxynucleotide • PCNA = proliferating cell nuclear antigen • PCR = polymerase chain reaction • PDGF = platelet derived growth factor • PGI2 = prostacyclin • PKC = protein kinase C • RCA = right coronary artery • RITA = right internal thoracic artery • Sca-1 = stem cell antigen-1 • Sdi-1 = senescent cell-derived inhibitor 1 (=p21) • SMC = smooth muscle cell • SOD = superoxide dismutase • TEM = transmission electron microscopy • TIMP = tissue inhibitor of MMP • TUNEL = terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labelling • VCAM = vascular cell adhesion molecule • VSMC = vascular smooth muscle cell

Key Words: Vein graft • CABG • Atherosclerosis • Neointima • Neointimal hyperplasia • Bypass




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
U. Reisinger, S. Schwaiger, I. Zeller, B. Messner, R. Stigler, D. Wiedemann, T. Mayr, C. Seger, T. Schachner, V. M. Dirsch, et al.
Leoligin, the major lignan from Edelweiss, inhibits intimal hyperplasia of venous bypass grafts
Cardiovasc Res, June 1, 2009; 82(3): 542 - 549.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. Kimura, K. Egashira, K. Nakano, E. Iwata, M. Miyagawa, H. Tsujimoto, K. Hara, Y. Kawashima, R. Tominaga, and K. Sunagawa
Local Delivery of Imatinib Mesylate (STI571)-Incorporated Nanoparticle Ex Vivo Suppresses Vein Graft Neointima Formation
Circulation, September 30, 2008; 118(14_suppl_1): S65 - S70.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
C. D Owens, K. J Ho, and M. S Conte
Lower extremity vein graft failure: a translational approach
Vascular Medicine, February 1, 2008; 13(1): 63 - 74.
[Abstract] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
T. Schachner, C. Steger, S. Heiss, N. Bonaros, W. Sterlacci, G. Laufer, and J. Bonatti
Paclitaxel treatment reduces neointimal hyperplasia in cultured human saphenous veins
Eur. J. Cardiothorac. Surg., December 1, 2007; 32(6): 906 - 911.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
G. M. Feuchtner, T. Schachner, J. Bonatti, G. J. Friedrich, P. Soegner, A. Klauser, and D. z. Nedden
Diagnostic Performance of 64-Slice Computed Tomography in Evaluation of Coronary Artery Bypass Grafts
Am. J. Roentgenol., September 1, 2007; 189(3): 574 - 580.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
T. Schachner
Reply to the Editor
J. Thorac. Cardiovasc. Surg., April 1, 2007; 133(4): 1119 - 1119.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2006 European Association for Cardio-Thoracic Surgery. Published by Elsevier. All rights reserved.